Skip to main content

Table 1 Patient response by model response type

From: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

  

Best response achieved over 24 months, n (%)

ELN response at 12 months, n (%)

Response type

All patients, n

CHR

CCyR

MMR

Optimal

Suboptimal

Warning or failure

Not assessable

Slow (monophasic)

65

47 (72.3)

5 (7.7)

1 (1.5)

2 (3.1)

2 (3.1)

39 (60.0)

22 (33.8)

Fast (biphasic)

58

57 (98.3)

51 (87.9)

41 (70.7)

40 (69.0)

7 (12.1)

4 (6.9)

7 (12.1)

  1. Abbreviations: CCyR = complete cytogenetic response; CHR = complete hematologic response; ELN = European LeukemiaNet; MMR = major molecular response.